2-(Anilinomethyl)imidazolines as α1A Adrenergic Receptor Agonists: 2′-Heteroaryl and 2′-Oxime Ether Series
摘要:
A series of 2'-heteroaryl and 2'-oxime anilinomethylimidazolines was prepared and evaluated in in vitro functional assays for cloned human alpha(1A), alpha(1B), and alpha(1D) receptor subtypes, Potent and selective alpha(1A) agonists have been identified in these series. (C) 2002 Elsevier Science Lid. All rights reserved.
Metal-catalyzed direct heteroarylation of C–H (<i>meso</i>) bonds in porphyrins: facile synthesis and photophysical properties of novel <i>meso</i>-heteroaromatic appended porphyrins
作者:Santosh B. Khandagale、Meenakshi Pilania、V. Arun、Dalip Kumar
DOI:10.1039/c8ob00174j
日期:——
A simple and rapid microwave-assisted synthesis of heteroaromatic appended porphyrins using the Pd/Cu-catalyzed C–C coupling of meso-bromoporphyrins with various five- and six-memberedheteroaromatic azoles has been successfully developed. The prepared heteroaromatic porphyrins 7a-lNi were found to exhibit slightly red-shifted (∼5–10 nm) Soret and Q bands. The developed reaction conditions are useful
已成功开发了一种介孔溴卟啉与各种五元和六元杂芳族吡咯的Pd / Cu催化C-C偶合的简单快速的微波辅助合成杂芳族附加卟啉的方法。发现制备的杂芳族卟啉7a-1Ni表现出轻微的红移(〜5-10 nm)Soret和Q谱带。所开发的反应条件可用于制备不同取代的杂芳族卟啉(A 3 B型和A 2 B 2型)。
Design, synthesis and biological evaluation of imidazole and oxazole fragments as HIV-1 integrase-LEDGF/p75 disruptors and inhibitors of microbial pathogens
作者:Thompho J. Rashamuse、Angela T. Harrison、Salerwe Mosebi、Sandy van Vuuren、E. Mabel Coyanis、Moira L. Bode
DOI:10.1016/j.bmc.2019.115210
日期:2020.1
We describe here the synthesis of libraries of novel 1-subtituted-5-aryl-1H-imidazole, 5-aryl-4-tosyl-4,5-dihydro-1,3-oxazole and 5-aryl-1,3-oxazole fragments via microwave (MW)-assisted cycloaddition of para-toluenesulfonylmethyl isocyanide (TosMIC) to imines and aldehydes. The compounds obtained were biologicallyevaluated in an AlphaScreen HIV-1 IN-LEDGF/p75 inhibition assay with six imidazole-based
Reaction Conditions for the Regiodivergent Direct Arylations at C2‐ or C5‐Positions of Oxazoles using Phosphine‐Free Palladium Catalysts
作者:Xinzhe Shi、Jean‐François Soulé、Henri Doucet
DOI:10.1002/adsc.201900641
日期:2019.10.22
The higher reactivity of C5‐H bond of oxazole as compared to the C2‐H bond in the presence of Pd(OAc)2/KOAc system is consistent with a concerted metalation deprotonation mechanism; whereas the C2‐arylation likely occurs via a simple base deprotonation of the oxazole C2‐position. Then, from these C2‐ or C5‐arylated oxazoles, a second palladium‐catalyzed direct C−H bond arylation affords 2,5‐diaryloxazoles
据报道,恶唑的C 2或C 5的区域直接芳基化有两个反应条件。在这两种情况下,均使用无膦催化剂和廉价的碱,从而以中等至高收率获得芳基化的恶唑。使用Pd(OAc)2 / KOAc作为催化剂和碱,可观察到区域选择性C5-芳基化;而使用Pd(acac)2 / Cs 2 CO 3系统,芳基化发生在恶唑的C2位。与存在Pd(OAc)2 / KOAc系统时的C2-H键相比,恶唑的C5-H键具有更高的反应活性,这与协同的金属化去质子化机理是一致的。而C2芳基化可能是通过恶唑C2位的简单碱基去质子化。然后,从这些C2或C5芳基恶唑中,进行第二次钯催化的直接C H键芳基化,得到具有两个不同芳基的2,5-二芳基恶唑。我们还通过三个CH键功能化步骤将这些顺序的芳基化反应用于2-芳基菲[9,10- d ]恶唑的直接合成。还描述了2-芳基恶唑的芳基单元的Ru催化的CH芳基化。
Syntheses of 4,5-Disubstituted Oxazoles via Regioselective C-4 Bromination
作者:Bryan Li、Richard A. Buzon、Zhijun Zhang
DOI:10.1021/op700176n
日期:2007.11.1
A scaleable and highly regioselective C-4 bromination of 5-substituted oxazoles is described. The use of DMF as solvent played a critical role in significantly improving the C-4/C-2 bromination ratio. The resulting 4-bromooxazoles were shown to be good Suzuki–Miyaura coupling partners with arylboronic acids. Furthermore, a simple and convenient method that employs triethylamine efficiently purged residual
A facilesynthesis of 4-aryl substituted oxazolo[4,5-c]quinolines has been described via a modified Pictet–Spengler method and using Cu(TFA)2 as a catalyst. The developed methodology directly functionalizes the C-4 position of oxazoles without the aid of any prefunctionalization, in the presence of the more reactive C-2 position in good yields. The versatility of the established method has been demonstrated
通过改进的Pictet-Spengler方法并使用Cu(TFA)2作为催化剂,已经描述了一种易于合成4-芳基取代的恶唑并[4,5- c ]喹啉的方法。在存在更高反应性的C-2位置的情况下,开发的方法无需任何预官能化即可直接将恶唑的C-4位置官能化。所建立方法的多功能性已通过其在合成4-取代的唑并-[1,8]萘啶环体系中的应用得到证实。